ACC Congress coverage: the interventional cardiology perspective

Preventive PCI or medical therapy alone for atherosclerotic coronary vulnerable plaques (PREVENT)

08 Apr 2024

Ali Nazmi Calik provides his take on the results of the PREVENT trial presented at ACC.24 in Atlanta.

Author

Ali Nazmi Calik

Preventive PCI or medical therapy alone for atherosclerotic coronary vulnerable plaques

Coronary sinus reducer for the treatment of refractory angina: A randomised, placebo-controlled trial (ORBITA-COSMIC)

08 Apr 2024

Aaysha Cader interviews Rasha Al-Lamee and Michael Foley about the results of the ORBITA-COSMIC trial presented at ACC.24 in Atlanta.

Results showed that coronary sinus reducer relieved angina symptoms but lacked evidence of increased blood flow to the heart. While beneficial for refractory angina patients, its mechanism remains...

Author

Rasha Al-Lamee

Author

Aaysha Cader

Author

Michael Foley

$ORBITA-COSMIC: Coronary sinus reducer for the treatment of refractory angina$

TAVI versus SAVR in patients at low to intermediate risk: One year outcomes of the randomized DEDICATE-DZHK6 Trial

08 Apr 2024

Luigi Biasco interviews Moritz Seiffert about the one-year outcomes of the randomized DEDICATE-DZHK6 trial which he presented at ACC.24 in Atlanta.

TAVR was found non-inferior to SAVR in low-risk patients, showing decreased rates of death or stroke at one year. The trial supports TAVR's safety and efficacy, highlighting...